Bicocca Open Archive

Logo unimib boa
MANTOVANI, LORENZO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.641
EU - Europa 11.410
AS - Asia 4.954
SA - Sud America 77
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 37
Totale 38.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.328
IT - Italia 3.006
SG - Singapore 1.808
DE - Germania 1.637
CN - Cina 1.570
IE - Irlanda 1.518
RU - Federazione Russa 1.447
SE - Svezia 1.372
HK - Hong Kong 818
UA - Ucraina 671
GB - Regno Unito 540
FR - Francia 299
CA - Canada 294
FI - Finlandia 236
DK - Danimarca 180
AT - Austria 174
IN - India 156
VN - Vietnam 156
ID - Indonesia 126
TR - Turchia 116
NL - Olanda 79
IR - Iran 49
BR - Brasile 47
BE - Belgio 46
CH - Svizzera 34
ES - Italia 30
EU - Europa 30
CZ - Repubblica Ceca 28
AU - Australia 27
KR - Corea 25
PK - Pakistan 24
JP - Giappone 21
PL - Polonia 21
RO - Romania 21
MX - Messico 17
NG - Nigeria 12
PH - Filippine 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
BD - Bangladesh 9
BG - Bulgaria 9
GR - Grecia 9
NO - Norvegia 9
OM - Oman 9
EG - Egitto 8
ET - Etiopia 8
TW - Taiwan 8
CO - Colombia 7
IQ - Iraq 7
AR - Argentina 6
A2 - ???statistics.table.value.countryCode.A2??? 5
TH - Thailandia 5
HR - Croazia 4
KE - Kenya 4
LK - Sri Lanka 4
LT - Lituania 4
MA - Marocco 4
MD - Moldavia 4
MK - Macedonia 4
MY - Malesia 4
RS - Serbia 4
SD - Sudan 4
KZ - Kazakistan 3
LV - Lettonia 3
PE - Perù 3
SA - Arabia Saudita 3
SC - Seychelles 3
ZA - Sudafrica 3
A1 - Anonimo 2
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
DZ - Algeria 2
EC - Ecuador 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
NP - Nepal 2
BA - Bosnia-Erzegovina 1
CU - Cuba 1
GH - Ghana 1
HN - Honduras 1
IM - Isola di Man 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
ME - Montenegro 1
MM - Myanmar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 38.205
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.737
Fairfield 1.958
Woodbridge 1.677
Singapore 1.537
Chandler 1.434
Dublin 1.413
Houston 1.204
Wilmington 1.164
Frankfurt am Main 1.141
Ashburn 1.137
Seattle 839
Hong Kong 802
Milan 748
Jacksonville 732
New York 708
Princeton 665
Cambridge 662
Santa Clara 653
Dearborn 640
Altamura 302
Lawrence 292
Nanjing 262
Vienna 167
Shanghai 157
San Diego 155
Beijing 132
Hangzhou 128
Rome 112
Jakarta 109
Lachine 104
Andover 100
Dong Ket 100
Helsinki 97
Shenyang 94
London 93
Nanchang 92
Saint Petersburg 87
Toronto 83
Guangzhou 82
Fremont 75
Boardman 73
Hebei 70
Jinan 65
Menlo Park 63
Tianjin 62
Norwalk 59
Jiaxing 57
Falls Church 53
Ottawa 51
Bologna 49
Changsha 48
Redmond 44
Ningbo 43
Zhengzhou 41
Los Angeles 38
Munich 37
Brussels 36
Lissone 35
Washington 35
Perugia 32
Lappeenranta 30
Moscow 30
Pune 29
Verona 29
Taizhou 28
Hefei 27
Palermo 26
Paris 25
Florence 24
Kunming 23
Chicago 22
Mountain View 22
Monza 21
Parma 21
Dallas 20
Bonndorf 19
Genoa 17
Brno 16
São Paulo 16
Boston 15
Edmonton 15
Huizen 15
Legnano 15
Napoli 15
Phoenix 15
Turin 15
Carate Brianza 14
Kocaeli 14
Nürnberg 14
Bergamo 13
Brescia 13
Duncan 13
Kazan 13
Pavia 13
Trieste 13
Collegeville 12
San Mateo 12
Hyderabad 11
Kilburn 11
New Delhi 11
Totale 27.392
Salva come PNG Salva come JPEG
Nome #
Costi dell’infarto miocardico acuto: analisi di dati sanitari amministrativi 748
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry 394
Administrative databases as a tool for identifying healthcare demand and costs in an over-one million population 347
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 327
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study 311
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 292
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 292
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 289
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 272
Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF 245
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 240
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 235
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study) 230
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 223
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? 222
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 216
Magnitude and time-course of excess mortality during COVID-19 outbreak: population-based empirical evidence from highly impacted provinces in northern Italy 204
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 195
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 195
Global, regional, and national burden of suicide mortality 1990 to 2016: Systematic analysis for the Global Burden of Disease Study 2016 195
Treatment of venous thromboembolism with tinzaparin in oncological patients 194
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 192
Occupational exposure in the lombardy region (Italy) to sars-cov-2 infection: Results from the mustang–occupation–covid-19 study 192
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 190
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 188
Health Related Quality of Life in the Major Liver Conditions 184
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 184
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry 183
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 181
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 180
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 178
The impact of liver disease on the health-related quality of life 177
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 177
Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 176
Health related quality of life in chronic liver diseases 176
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity 174
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 173
Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry 173
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 172
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 172
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 170
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 170
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis 170
Medical Costs And Resources Consumption In Patients With Atrial Fibrillation: An Italian Observational Study 170
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 169
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 169
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 169
Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy 169
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 168
Sustainability of the Italian National Health Service 168
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 167
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 166
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 166
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 164
Costs and effectiveness of influenza vaccination: A systematic review 164
Impatto clinico ed economico della gestione dei rialzi pressori in gravidanza in regime di pronto soccorso: il possibile ruolo dei marcatori biochimici 164
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 163
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America 162
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 161
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 160
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 159
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 159
Implantable Cardioverter Defibrillator in Italy from 2000 to 2008: a population-based analysis using health administrative databases. 158
Persistence and adherence to hypolipemic therapy in real practice: Results of a large administrative database 157
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation 157
Cost and outcomes after first acute myocardial infarction: study on 12049 individuals using administrative databases 156
Economic Burden Of Stroke: Analysis From An Administrative Database 155
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 155
The socioeconomic burden of patients affected by hemophilia with inhibitors 154
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation 152
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists 152
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 151
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 151
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: Co-medication interactions 151
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases 150
Resource utilization and costs for patients with inflammatory bowel diseases in italy: a population-based assessment 148
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 148
New pharmacoeconomic option in uremic anemia management [3] 148
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 148
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 145
The Economic Impact of The use of Implantable Cardioverter Defibrillator In Primary Prevention 144
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 143
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 142
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 142
The Cost Of Illness Of Atrial Fibrillation In Italy: A Cohort Of Hospitalized Patients 141
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 140
Epidemiology and Direct Health Care Costs of Diabetic Retinopathy: Results From a Population-Based Study 140
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities 140
Implantable cardioverter defibrillator (ICD) in Italy from 2000 to 2008: a population-based analysis using health administrative databases 139
Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases 139
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 139
Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A 138
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation 137
The economic impact of air pollution: a European assessment 136
Economic burden of pneumoniae requiring hospitalization in italy: analysis from an administrative database 135
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 135
Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective 135
Use of health care administrative databases to estimate the burden of breast cancer. 134
Marginal structural models used in estimating cost-effectiveness of time-varying drug therapy using administrative databases. the case of statin in secondary prevention. 130
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 130
Totale 18.430
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.788
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.748 0 0 0 0 486 724 730 495 552 323 318 120
2020/20216.836 668 445 713 524 590 615 699 682 567 512 363 458
2021/20223.998 321 391 400 360 275 301 196 248 234 295 280 697
2022/20236.447 781 1.873 536 518 455 977 74 355 480 93 182 123
2023/20245.455 171 247 185 271 681 1.299 859 195 525 158 235 629
2024/20255.257 811 1.811 751 740 1.144 0 0 0 0 0 0 0
Totale 40.278